

SAFETY DATA SHEET

SECTION 1: IDENTIFICATION

Fosphenytoin Sodium Injection, USP Product Name:

Manufacturer Name: Fresenius Kabi USA, LLC Three Corporate Drive Address: Lake Zurich, Illinois 60047

(847) 550-2300

General Phone Number: Customer Service Phone

(888) 386-1300

(800) 551-7176 Health Issues Information: SDS Creation Date: January 08, 2009 SDS Revision Date: October 04, 2024

SECTION 2: HAZARD(S) IDENTIFICATION

GHS Pictograms:







Signal Word: DANGER.

GHS Class: Serious Eye Damage. category 1.

Skin corrosion. category 1. Respiratory sensitisation. category 1. Reproductive toxicity. Category 1A. Skin Sensitization. category 1.

Reproductive toxicity. Effects on or via lactation.

Hazard Statements: Causes serious eye damage.

Causes severe skin burns and eye damage. May cause allergy or asthma symptoms or breathing difficulties if inhaled.

May damage fertility or the unborn child. May cause an allergic skin reaction. May cause harm to breast-fed children.

Precautionary Statements: Obtain special instructions before use.

Do not handle until all safety precautions have been read and understood. Do not breathe ${\tt dust/fume/gas/mist/vapours/spray}.$

Avoid breathing dust/fume/gas/mist/vapours/spray. Avoid contact during pregnancy and while nursing.

Wash hands thoroughly after handling.
Do not eat, drink or smoke when using this product.
Contaminated work clothing should not be allowed out of the workplace.

Wear protective gloves/protective clothing/eye protection/face protection. In case of inadequate ventilation wear respiratory protection.

IF SWALLOWED: Rinse mouth. Do not induce vomiting.
IF ON SKIN: Wash with plenty of water.
IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with

water/shower.

IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. $IF \ IN \ EYES: \ Rinse \ cautiously \ with \ water for several \ minutes. \ Remove \ contact \ lenses, \ if \ present \ and \ easy to \ do. \ Continue \ rinsing.$

IF exposed or concerned: Get medical advice/attention. Immediately call a POISON CENTER or doctor/physician.

Specific treatment (see ... on this label). If skin irritation or rash occurs: Get medical advice/attention.

If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.

Take off contaminated clothing and wash it before reuse. Wash contaminated clothing before reuse.

Store locked up.
Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse

reactions from prescribed doses and overdoses are described in the package insert

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eye: Contact with eyes may cause irritation.

Signs/Symptoms: Potential adverse reactions from prescribed doses are described in the package insert and include: nausea, vomiting, lethargy, tachycardia, bradycardia, asystole, cardiac arrest, hypotension, syncope, hypocalcemia, metabolic acidosis, and death have been reported in cases of overdosage with

fosphenytoin. Treatment is nonspecific since there is no known antidote to Fosphenytoin Sodium or

phenytoin overdose. Occupational exposure has not been fully investigated.

Aggravation of Pre-Existing

Conditions:

Individuals with hypersensitivity to Fosphenytoin Sodium Injection or its ingredients or to phenytoin or other hydantoins. Individuals with sinus bradycardia, sino-atrial block, second and third degree A-V block, and Adams- Strokes syndrome.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name CAS# **Ingredient Percent** EC Num.

Fosphenytoin Sodium 92134-98-0 75 mg/mL

77-86-1 As Buffer Tromethamine

Water for Injection 7732-18-5 Quantity Sufficient

SECTION 4: FIRST AID MEASURES

Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of Eye Contact:

the eyes by separating the eyelids with fingers. Get immediate medical attention.

Skin Contact: Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing

contaminated clothing and shoes. Get medical attention if irritation develops or persists.

Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained

personnel. Seek immediate medical attention

If conscious, flush mouth out with water immediately. Call a physician or poison control center Inaestion:

immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give

anything by mouth to an unconscious person.

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

SECTION 5: FIRE FIGHTING MEASURES

Flash Point: Not established. Not established. Flash Point Method: Not established. Auto Ignition Temperature: Lower Flammable/Explosive Limit: Not established. Upper Flammable/Explosive Limit: Not established.

Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to Fire Fighting Instructions:

minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible,

contain fire run-off water.

Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires Extinguishing Media:

involving this material.

Use extinguishing measures that are appropriate to local circumstances and the surrounding

environment.

Protective Equipment: As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.

Hazardous Combustion

Byproducts:

Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of

combustion

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal Precautions: Evacuate area and keep unnecessary and unprotected personnel from entering the spill area.

Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as

listed in Section 8.

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods for containment: Contain spills with an inert absorbent material such as soil, sand or oil dry.

Methods for cleanup: Absorb spill with inert material (e,g., dry sand or earth), then place in a chemical waste container. After

removal, flush spill area with soap and water to remove trace residue.

SECTION 7: HANDLING and STORAGE

Handling: When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes.

Use with adequate ventilation. Use only in accordance with directions

Store at refrigerated temperatures 2 to 8°C (36 to 46°F). Storage:

Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety Work Practices:

shower.

Hygiene Practices: Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, **Engineering Controls:**

hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended

exposure limits.

Eye/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist.

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data.

Nitrile rubber or natural rubber gloves are recommended

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being

used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site

(http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal

protective equipment.

EXPOSURE GUIDELINES

SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

Physical State: Liquid solution. Color: Clear to pale yellow

Boiling Point: 100°C

Meltina Point: Not established. Soluble, in water, Solubility: Vapor Density: Not established. Vapor Pressure: Not established. Percent Volatile: Not established. 8.6 - 9.0

Molecular Formula: Mixture 406.24 Molecular Weight:

Flash Point: Not established. Flash Point Method: Not established. Auto Ignition Temperature: Not established.

SECTION 10: STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

Hazardous Polymerization: Not reported.

Conditions to Avoid: Avoid direct sunlight, conditions that might generate heat, and sources of ignition.

SECTION 11: TOXICOLOGICAL INFORMATION

Fosphenytoin Sodium:

Acute Toxicity:

LD50 IV: Rat 363 mg/kg LD50 IV (bolus): Rat 319.2 mg/kg

Pregnancy Category D: Prenatal exposure to phenytoin may increase the risks for congenital Teratogenicity:

malformations and other adverse developmental outcomes. Increased frequencies of major malformations, minor anomalies, growth abnormalities, and mental deficiency have been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy.

OSHA Label: CAUTION Antiepileptic drug: may cause nervous system effects. Possible carcinogen.

Possible risk of harm to the unborn child.

Fosphenytoin Sodium:

Inhalation: LC50 IV: Mouse 234 mg/kg Other Toxicological Information: LD50 IV: Rat 363 mg/kg

LD50 IV (bolus): Rat 319.2 mg/kg

Tromethamine:

RTECS Number: TY2900000

Ingestion: Oral - Rat LD50 : 5900 mg/kg [Details of toxic effects not reported other than lethal dose value]

 $Intravenous. - Rat\ LD50: 1800\ mg/kg\ [Details\ of\ toxic\ effects\ not\ reported\ other\ than\ lethal\ dose$ Other Toxicological Information:

value]

Intravenous. - Mouse LD50 : 1210 mg/kg [Details of toxic effects not reported other than lethal dose

value]

SECTION 12: ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.

Environmental Stability: No environmental information found for this product.

SECTION 13: DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated. DOT UN Number: Not Regulated.

SECTION 15: REGULATORY INFORMATION

Tromethamine:

TSCA Inventory Status: Listed EINECS Number: 201-064-4 Canada DSL: Listed

SECTION 16: ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 2* HMIS Fire Hazard: n HMIS Reactivity: 0 **HMIS Personal Protection:**

SDS Creation Date: January 08, 2009 SDS Revision Date: October 04, 2024

SDS Revision Notes: Overall SDS review - no changes to formulation. Added USP to the product name in Section

1 (to read as 'Fosphenytoin Sodium Injection, USP') and added HMIS ratings for Health, Flammability, Reactivity, and Personal Protective Equipment (PPE) in Section 16.

Disclaimer: The information contained herein pertains to this material. It is the responsibility of each individual

party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2018 Enviance. All Rights Reserved.